左甲状腺素治疗对亚临床甲状腺功能减退症生育与妊娠结局的影响:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入5项孕前治疗研究(768例)和8项妊娠早期治疗研究(2622例),评估左甲状腺素对亚临床甲状腺功能减退症生育与妊娠结局的疗效。孕前左甲状腺素治疗未显著改善活产率、妊娠率或降低流产率;妊娠期治疗对早产的影响因促甲状腺激素水平而异,仅在促甲状腺激素>4.0 mU/L亚组显示有利效果。
要点
- 孕前左甲状腺素治疗未显著改善活产率、妊娠率或降低流产率。
- 妊娠期左甲状腺素治疗对早产的影响因促甲状腺激素水平不同而存在显著差异(p=0.04)。
- 促甲状腺激素>4.0 mU/L亚组早产风险比为0.47(0.20-1.10),2.5-4.0 mU/L亚组为1.35(0.79-2.31)。
核心结论
- 孕前左甲状腺素治疗亚临床甲状腺功能减退症不改善生育力或降低流产发生率。
- 妊娠期左甲状腺素治疗对早产有积极影响,但仅适用于促甲状腺激素>4.0 mU/L的亚临床甲状腺功能减退症。
- 孕前治疗尤其是促甲状腺激素>4.0 mU/L者仍需进一步设计良好的研究。
研究设计与样本
- 系统综述与Meta分析,检索随机对照试验,检索时间从建库至2023年2月。
- 共识别888项研究,筛选27篇全文,最终分析5项孕前治疗研究(768例)和8项妊娠早期治疗研究(2622例)。
- 孕前治疗研究中,促甲状腺激素>4.0 mU/L的两项研究里,一项高偏倚风险,另一项由64例参与者组成。
主要发现
- 孕前左甲状腺素治疗对活产率、妊娠率、流产率的影响无显著效果,风险比(95%置信区间)分别为1.41(0.84-2.36)、1.73(0.88-3.39)、0.46(0.11-2.00)。
- 妊娠期左甲状腺素治疗与活产率升高无显著关联(风险比1.03,0.98-1.09),与流产率降低也无显著关联(风险比1.01,0.66-1.53)。
- 妊娠期左甲状腺素治疗对早产的影响因促甲状腺激素值不同而存在显著差异(p=0.04)。
- 促甲状腺激素>4.0 mU/L亚组显示对早产有积极效果(风险比0.47,0.20-1.10),促甲状腺激素2.5-4.0 mU/L亚组未观察到显著效果(风险比1.35,0.79-2.31)。
关键数值与推荐
- 亚临床甲状腺功能减退症定义为促甲状腺激素升高且游离甲状腺素水平正常。
- 左甲状腺素治疗前促甲状腺激素阈值水平为2.5 mU/L。
- 孕前治疗主要结局为活产、妊娠、流产;妊娠期治疗主要结局为活产、流产、早产。
- 亚组分析比较促甲状腺激素2.5-4.0 mU/L与>4.0 mU/L的亚临床甲状腺功能减退症。
临床怎么用
- 孕前左甲状腺素治疗亚临床甲状腺功能减退症不改善生育力或降低流产发生率。
- 妊娠期左甲状腺素治疗对早产的积极影响仅适用于促甲状腺激素>4.0 mU/L的亚临床甲状腺功能减退症。
- 孕前治疗尤其是促甲状腺激素>4.0 mU/L者需进一步设计良好的研究。
局限性
- 孕前治疗研究中促甲状腺激素>4.0 mU/L的两项研究里,一项高偏倚风险,另一项由64例参与者组成。
- 孕前治疗尤其是促甲状腺激素>4.0 mU/L者需进一步设计良好的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Subclinical hypothyroidism, defined by elevated thyrotropin (TSH) and normal free thyroxine levels, is associated with adverse pregnancy outcomes, including preterm birth, pre-eclampsia, and small for gestational age. Despite the uncertainty regarding the effectiveness of levothyroxine (LT4) treatment on pregnancy outcomes in subclinical hypothyroidism, LT4 is widely administered with a pre-treatment threshold TSH level of 2.5 mU/L. The aim of this study is to investigate the efficacy of periconceptional LT4 treatment for subclinical hypothyroidism, including TSH levels >2.5 mU/L, and identify the characteristics of subclinical hypothyroidism that can benefit from LT4 treatment. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials from inception to February 2023. We analyzed the pooled effects of LT4 on subclinical hypothyroidism before and during pregnancy. The main outcomes before pregnancy were live birth, pregnancy, and miscarriage. The main outcomes during pregnancy were live birth, miscarriage, and preterm birth. We conducted subgroup analyses to compare the effects of LT4 on subclinical hypothyroidism with TSH levels of 2.5-4.0 and >4.0 mU/L. Results: Of the 888 studies identified, 27 full-text articles were screened for eligibility. Five studies on pre-conception treatment with 768 participants and eight studies on treatment during early pregnancy with 2622 participants were analyzed. One of the two studies on pre-conception treatment in subclinical hypothyroidism with TSH >4.0 mU/L had high risk of bias and the other was composed of 64 participants. Pre-conception LT4 treatment had no significant effect in improving rates of live births and pregnancies, or reducing miscarriages (risk ratio [RR], 95% confidence interval): 1.41 (0.84-2.36), 1.73 (0.88-3.39), and 0.46 (0.11-2.00), respectively. LT4 treatment during pregnancy was not significantly associated with higher rates of live births (RR 1.03, 0.98-1.09) nor decreased miscarriage rates (RR 1.01, 0.66-1.53). The effect of LT4 treatment on preterm birth during pregnancy was significantly different depending on the TSH values (p = 0.04); a positive effect was shown in the subclinical hypothyroidism subgroup with TSH >4.0 mU/L (RR 0.47, 0.20-1.10), while no significant effect was observed in the subgroup with TSH 2.5-4.0 mU/L (RR 1.35, 0.79-2.31). Conclusions: Pre-conceptional LT4 treatment for subclinical hypothyroidism does not improve fertility or decrease the incidence of miscarriages. However, further well-designed studies are needed for pre-conceptional treatment, especially in TSH >4.0 mU/L. LT4 treatment during pregnancy had a positive effect on preterm birth; nevertheless, this was only applicable to subclinical hypothyroidism with TSH >4.0 mU/L.
引用
- Sankoda A, Suzuki H, Imaizumi M, et al. Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Thyroid. 2024. PMID: 38368537. doi:10.1089/thy.2023.0546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。